<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929353</url>
  </required_header>
  <id_info>
    <org_study_id>IRMA</org_study_id>
    <nct_id>NCT04929353</nct_id>
  </id_info>
  <brief_title>SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS</brief_title>
  <acronym>IRMA</acronym>
  <official_title>(ImmunotheRapy SyMptom CApture) A RANDOMIZED CONTROLLED TRIAL OF SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune-related adverse events (irAEs) can be different in their onset, kinetics and&#xD;
      presentation but unlike chemotherapy are seldom predictable. Toxicity can affect nearly any&#xD;
      organ system and multiple presentations of rare but severe irAEs have been reported,&#xD;
      highlighting the relevance of vigilant monitoring.&#xD;
&#xD;
      Although early detection and timely management of high grade or special interest irAEs (such&#xD;
      as cardiac and neurological) is obvious, it is unclear whether early identification of less&#xD;
      serious events can lead to clinical benefit. Furthermore, it is of the utmost importance to&#xD;
      develop new tools which can increase identification of side effects. The current study&#xD;
      investigates systematic symptom assessment through an electronic patient reported outcome&#xD;
      tool and aims to define whether this can reduce the rate of serious irAEs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systematic collection of symptom information during immunotherapy treatment will be compared&#xD;
      to usual care in locally advanced or metastatic lung cancer (NSCLC or SCLC) and surgically&#xD;
      resected or advanced melanoma. Electronic survey will be administered every other day to&#xD;
      report 14 common symptoms selected from the NCI-PRO-CTCAE TM library developed by the&#xD;
      NATIONAL CANCER INSTITUTE (NATIONAL INSTITUTES OF HEALTH, Bethesda, Maryland) Italian version&#xD;
      (NCI-PRO-CTCAETM ITEMS-ITALIAN-Item Library Version 1.0).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Decrease rate of irAEs ≥ grade 3 according to CTCAEs (Common Terminology Criteria for Adverse Events) with systematic symptom assessment</measure>
    <time_frame>36 months</time_frame>
    <description>The electronic questionnaire surveys 14 symptoms selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0). The patient will rate their symptoms on a 5-point ordinal scale concerning the symptom frequency (never / rarely / sometimes / often / almost always), intensity (not at all / a little / quite / a lot / very much) and sometimes their interference with usual/daily activities (not at all / a little / quite / a lot / very much). The questionnaire must be collected from all patients (ARM A and ARM B) after randomization and before first treatment administration. Patients enrolled in ARM A must answer the questionnaire every other day. Alert will then be triggered when symptom level is not within the designated range. Following every activated alert, a physical examination and biochemical blood tests must be carried out.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Duration of irAEs ≥ grade 3</measure>
    <time_frame>36 months</time_frame>
    <description>Duration of irAEs ≥ grade 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Emergency hospital admission</measure>
    <time_frame>36 months</time_frame>
    <description>Emergency hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Admission to and duration of hospitalization</measure>
    <time_frame>36 months</time_frame>
    <description>Admission to and duration of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Melanoma</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Self-Reporting by electronic survey consisting of 14 items selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard symptom reporting following the conventional modalities of clinical oncology practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systematic symptom assessment</intervention_name>
    <description>Systematic symptom assessment&#xD;
Conventional symptom assessment</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old at time of signing Informed Consent Form&#xD;
&#xD;
          -  Histologically documented diagnosis of locally advanced or metastatic lung cancer&#xD;
             (NSCLC or SCLC), surgically resected or advanced melanoma&#xD;
&#xD;
          -  Patients eligible for immunotherapy in any line of treatment, either alone or in&#xD;
             combination with other immunotherapy drugs or with chemotherapy&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Life expectancy ≥3 months&#xD;
&#xD;
          -  ECOG Performance Status of ≤2&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, defined by laboratory test result by&#xD;
             investigator's judgment&#xD;
&#xD;
          -  Viral hepatitis screening:&#xD;
&#xD;
               1. Negative hepatitis B surface antigen (HBsAg) test&#xD;
&#xD;
               2. For patients with positive total HBcAb test, hepatitis B virus (HBV) DNA test is&#xD;
                  required&#xD;
&#xD;
               3. For patients with positive HCV antibody test, hepatitis C virus (HCV) RNA test is&#xD;
                  required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving immunotherapy at time of enrollment&#xD;
&#xD;
          -  &gt; 1 grade adverse events from previous treatments&#xD;
&#xD;
          -  Any uncontrolled symptom&#xD;
&#xD;
          -  Clinically unstable brain metastases (i.e., symptomatic, not treated with RT and&#xD;
             rapidly evolving)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncologia Medica, Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>ROILA FAUSTO</last_name>
      <phone>+39 075 585 8167</phone>
      <email>fausto.roila@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>CURRA MARIA FRANCESCA</last_name>
      <phone>+39 075 578 4188</phone>
      <email>mfrancesca.curra@ospedale.perugia</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Roila Fausto</investigator_full_name>
    <investigator_title>Professor of Medical Oncology at the University of Perugia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

